Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Evolving Landscape of HER2 Targeting in Breast Cancer.

JAMA oncology - 1 Nov 2015

Moasser Mark M, Krop Ian E

Abstract excerpt

The development of human epidermal growth factor receptor 2 (HER2)-targeting agents for the treatment of HER2-amplified breast cancer has dramatically improved outcomes for patients with this disease. The value of HER2 as a therapeutic target encompasses 2 entirely different mechanistic dimensions. The first approach exploits the fact that HER2 is clearly a disease-driving oncogene to deliver HER2 kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Treatment Outcome

Source

Identifiers

PMID: 26204261
DOI: 10.1001/jamaoncol.2015.2286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Evolving Landscape of HER2 Targeting in Breast Cancer.PMID 26204261Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Semantic proximity Read ↗

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various CancersSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read ↗

The human epidermal growth factor receptor 2 (HER2)Semantic proximity Read ↗

HER2: Biology, Detection, and Clinical ImplicationsSemantic proximity Read ↗

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.